Compare Novartis AG (NVS) vs Stanley Black & Decker, Inc. (SWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Stanley Black & Decker, Inc. — how do they compare? Novartis AG trades at $152.77 (market cap $295.37B), while Stanley Black & Decker, Inc. trades at $104.1 (market cap $15.71B). The key difference: Novartis AG is far larger — about 18.8× Stanley Black & Decker, Inc.'s market cap, and Stanley Black & Decker, Inc. pays the higher dividend (3.23%). Which is the better fit depends on your goals.
| NVS | SWK | |
|---|---|---|
Market Cap | $295.37B | $15.71B |
Sector | Health | — |
52-Week High | $168.62 | $104.00 |
52-Week Low | $119.31 | $62.12 |
Enterprise Value | $336.69B | $19.87B |
Dividend Yield | 3.07% | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
Stanley Black & Decker (SWK) trades at $102.64, down 1.2% on the day, with a bullish technical signal from moving averages but overbought RSI readings. Recent Q2 2026 earnings beat expectations with EPS of $1.57 versus $1.21 expected, driven by margin expansion and strong organic growth. The company announced a $1 billion U.S. investment plan to boost manufacturing and innovation, signaling strategic growth commitment.
The outlook is positive with improving profitability and debt reduction, but risks include competitive pressures and economic sensitivity. Analysts are mixed with a $93.67 consensus target below current price, suggesting cautious optimism. Upside hinges on continued execution of cost savings and market share gains in tools and infrastructure sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →
